NCT01186458 - Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions

Lymphoma, Non-Hodgkin

Interventions

DRUG

Fludarabine

Fludarabine 25 mg/m2 IV over 30 minutes on days 1, 2, 4. Cycle = 28 days; maximum of 6 cycles of therapy.

DRUG

Velcade

Velcade (given after fludarabine)1.3 mg/m2 IV push over 3 to 5 seconds on days 1, 4, 8, 11. Cycle = 28 days; maximum of 6 cycles of therapy.

DRUG

Rituximab

Rituximab given after Velcade) 375 mg/m2 IV piggyback on day 1. Cycle = 28 days; maximum of 6 cycles of therapy.

Trial Locations (11)

University of Rochester Medical Center, Rochester

Reading Hospital Regional Cancer Center, West Reading

Case Comprehensive Cancer Center - University Hospitals Case Medical Center, Cleveland

Seidman Cancer Center, Cleveland

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

Community Regional Cancer Center, Indianapolis

Fort Wayne Oncology & Hematology, Inc, Fort Wayne

Cancer Care Center of Southern Indiana, Bloomington

Arnett Cancer Care, Lafayette

Virtua Health Cancer Program, Mount Holly

South Jersey Health Care, Vineland